Next Article in Journal
Plasma Proteomic Analysis in Morquio A Disease
Next Article in Special Issue
Albumin-Coated Single-Core Iron Oxide Nanoparticles for Enhanced Molecular Magnetic Imaging (MRI/MPI)
Previous Article in Journal
Candida Cell-Surface-Specific Monoclonal Antibodies Protect Mice against Candida auris Invasive Infection
Previous Article in Special Issue
The Design of Abnormal Microenvironment Responsive MRI Nanoprobe and Its Application
Review

Diagnostics and Therapeutics in Targeting HER2 Breast Cancer: A Novel Approach

1
School of Medicine, Deakin University, Geelong, VIC 3220, Australia
2
Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University, Geelong, VIC 3220, Australia
*
Author to whom correspondence should be addressed.
Academic Editor: Manuela Malatesta
Int. J. Mol. Sci. 2021, 22(11), 6163; https://doi.org/10.3390/ijms22116163
Received: 30 April 2021 / Revised: 25 May 2021 / Accepted: 30 May 2021 / Published: 7 June 2021
(This article belongs to the Special Issue Molecular Imaging in Nanomedical Research 2.0)
Breast cancer is one of the most commonly occurring cancers in women globally and is the primary cause of cancer mortality in females. BC is highly heterogeneous with various phenotypic expressions. The overexpression of HER2 is responsible for 15–30% of all invasive BC and is strongly associated with malignant behaviours, poor prognosis and decline in overall survival. Molecular imaging offers advantages over conventional imaging modalities, as it provides more sensitive and specific detection of tumours, as these techniques measure the biological and physiological processes at the cellular level to visualise the disease. Early detection and diagnosis of BC is crucial to improving clinical outcomes and prognosis. While HER2-specific antibodies and nanobodies may improve the sensitivity and specificity of molecular imaging, the radioisotope conjugation process may interfere with and may compromise their binding functionalities. Aptamers are single-stranded oligonucleotides capable of targeting biomarkers with remarkable binding specificity and affinity. Aptamers can be functionalised with radioisotopes without compromising target specificity. The attachment of different radioisotopes can determine the aptamer’s functionality in the treatment of HER2(+) BC. Several HER2 aptamers and investigations of them have been described and evaluated in this paper. We also provide recommendations for future studies with HER2 aptamers to target HER2(+) BC. View Full-Text
Keywords: aptamers; HER2; breast cancer; radiolabelling; radioisotopes; antibodies; nanobodies; imaging; diagnosis; cancer aptamers; HER2; breast cancer; radiolabelling; radioisotopes; antibodies; nanobodies; imaging; diagnosis; cancer
Show Figures

Figure 1

MDPI and ACS Style

Vi, C.; Mandarano, G.; Shigdar, S. Diagnostics and Therapeutics in Targeting HER2 Breast Cancer: A Novel Approach. Int. J. Mol. Sci. 2021, 22, 6163. https://doi.org/10.3390/ijms22116163

AMA Style

Vi C, Mandarano G, Shigdar S. Diagnostics and Therapeutics in Targeting HER2 Breast Cancer: A Novel Approach. International Journal of Molecular Sciences. 2021; 22(11):6163. https://doi.org/10.3390/ijms22116163

Chicago/Turabian Style

Vi, Chris, Giovanni Mandarano, and Sarah Shigdar. 2021. "Diagnostics and Therapeutics in Targeting HER2 Breast Cancer: A Novel Approach" International Journal of Molecular Sciences 22, no. 11: 6163. https://doi.org/10.3390/ijms22116163

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop